Share Icon Health Study Area: Cardiovascular Disease Chevron Icon Health Study Area: Genitourinary For Patients Health Study Area: Lung Cancer Page Icon Phone Icon For Caregivers Health Study Area: AutoImmune Disease Health Study Area: Melanoma Location Icon Print YouTube Icon For Parents Health Study Area: Lung Cancer Print Created with Sketch. Help Icon Green Check Icon Search Icon Instagram Created with sketchtool. Direction Arrow Icon Error Icon For Parents Health Study Area: Blood Cancer Help Icon Health Study Area: NASH Gender Both Bookmark Icon Health Study Area: Melanoma Created with Sketch. Glossary Print Health Study Area: Blood Cancer Health Study Area: Genitourinary Health Study Area: Gastrointestinal Cancer Mobile Menu Icon Created with Sketch. Health Study Area: Cardiovascular Disease Health Study Area: Women's Cancer Communities Map Icon Created with Sketch. For Caregivers Health Study Area: Fibrosis Health Study Area: AutoImmune Disease FAQs Health Study Area: Head and Neck Cancer Created with Sketch. For Clinicians Chevron Right Icon Gender Female Health Study Area: Breast Cancer Direction Arrow Icon Gender Both Right Arrow Icon LinkedIn Icon Green Check Icon Gender Male Health Study Area: Fibrosis For Patients Twitter Icon Email Icon Facebook Icon Health Study Area: Gastrointestinal Cancer Health Study Area: Head and Neck Cancer For Clinicians External Link Icon

Menú

Buscar estudios clínicos de BMS
Ícono de BMS, estudio No reclutando aún

Not Yet Recruiting

ID del estudio CA061-1005  |   NCT07335562

A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacaptagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis

Ícono de advertencia
Lo sentimos, este estudio aún no acepta participantes.
Marque esta página como favorita para volver a consultarla en una fecha posterior.  También puede hacer clic en el botón “Verificar su elegibilidad” y responder algunas preguntas sobre su salud para averiguar si podría ser compatible con otro estudio.
Verifique su elegibilidad

Resumen

  • Phase 3
  • Ícono de género masculino y femenino
  • 16+
  • 9
  • Ícono de BMS, estudio No reclutando aún
    Not Yet Recruiting

Descripción general

The purpose of this study is to compare the efficacy and safety of BMS-986353 versus standard of care in participants with active Systemic Sclerosis

Imprimir Imprimir
Email Correo electrónico

Criterios clave de elegibilidad

Criterios de inclusión

Criterios de inclusión Icon
  • Participants must fulfill the 2013 American College of Rheumatology (ACR) / European League Against Rheumatism (EULAR) classification criteria for Systemic Sclerosis (SSc), and additionally have the following:.
    1. Positive Antinuclear Antibodies (ANA) with nucleolar pattern and/or anti-Topoisomerase I (anti-Scl-70) antibodies.
      1. Confirmation of Interstitial Lung Disease (ILD) on centrally read High-Resolution Computed Tomography (HRCT) with ≥ 10% total lung involvement, with at least one of the following attributed to active SSc:.
        1. Arthritis.
        2. Myositis.
        3. Carditis.
        4. Progressive skin disease.
        5. Elevated inflammatory markers.
    2. Participants must have a non-response or intolerance despite ≥ 6 months of treatment with at least one immunomodulatory drug. Non-response is defined as a patient, who in the opinion of the investigator, is not adequately controlled/treated and requires treatment escalation.

      Criterios de exclusión

      Criterios de exclusión Icon
      • Participants must not have a requirement for supplemental oxygen therapy and/or Diffusing Capacity of the Lungs for Carbon Monoxide (DLCO) ≤ 40% (Hemoglobin (Hgb) corrected) at screening.
        1. Participants must not have moderate to severe Pulmonary Arterial Hypertension (PAH) requiring PAH-specific combination treatment
          1. Participants must not have pulmonary comorbidity including chronic obstructive pulmonary disease or asthma requiring daily oral corticosteroids, cigarette smoking (including e-cigarettes) within 3 months before screening or unwilling to avoid smoking throughout the study, and/or clinically significant abnormalities on HRCT not attributable to SSc assessed by the central reader at screening.
            1. Participants must not have gastrointestinal (GI) dysmotility requiring Total Parenteral Nutrition (TPN).
              1. Participants must not have current gangrene of a digit
                Información Adicional *
                • Other protocol-defined Inclusion/Exclusion criteria apply.

                  Opciones de tratamiento

                  Brazos del estudio

                  INTERVENCIÓN ASIGNADA

                  Brazos del estudio

                  Experimental: Arm A: BMS-986353

                  INTERVENCIÓN ASIGNADA
                  • Drug: BMS-986353, Fludarabine, Cyclophosphamide

                  Brazos del estudio

                  Experimental: Arm B: Standard of Care

                  INTERVENCIÓN ASIGNADA
                  • Drug: Tocilizumab, Rituximab, Nintedanib
                  Vuelva a consultar más tarde para encontrar un sitio de reclutamiento o encuentre otro estudio haciendo clic en “Verificar su elegibilidad”
                  Verifique su elegibilidad
                  Responda algunas preguntas sobre su salud para ver si puede ser compatible con este enstudio.
                  Compatibilizar con un estudio
                  Si es compatible, haga clic en el estudio para ver la lista de ubicaciones de los centros del estudio.
                  Seleccione una ubicación del centro del estudio
                  Seleccione una ubicación del centro del estudio que sea conveniente para usted
                  Registrarse
                  Proporcione sus datos de contacto para que el centro del estudio se comunique con usted.

                  Ayúdenos a mejorar su experiencia en el sitio web. Comparta sus comentarios con nuestro equipo en BMS Clinical Trials para mejorar su experiencia y la de los demás. Gracias